Table 4.
Characteristics of patients in the LP/completed and LP/dropped out groups.
| LP/completed |
LP/dropped out |
p-value | |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| n | 48 | 22 | |
| Age (years) | 70.2 ± 6.7 | 70.9 ± 6.8 | 0.67 |
| Prostate volume (ml) | 64.2 ± 18.9 | 66.6 ± 15.5 | 0.60 |
| PSA (ng/ml) | 6.0 ± 5.0 | 6.6 ± 3.7 | 0.58 |
| IPSS-total | 19.3 ± 7.1 | 19.7 ± 4.9 | 0.76 |
| IPSS-voiding | 11.0 ± 5.1 | 12.0 ± 3.5 | 0.41 |
| IPSS-storage | 8.3 ± 2.6 | 7.7 ± 2.0 | 0.36 |
| IPSS-QOL | 4.7 ± 0.8 | 5.0 ± 0.6 | 0.12 |
| OABSS | 7.0 ± 2.6 | 6.0 ± 1.9 | 0.16 |
| Qmax (ml/s) on UFM | 8.2 ± 3.5 | 6.5 ± 2.3 | 0.04 |
| PVR (ml) on UFM | 68 ± 59 | 82 ± 50 | 0.35 |
| IPP (mm) | 13.6 ± 6.0 | 17.7 ± 4.6 | 0.006 |
| BOOI | 71.8 ± 26.6 | 84.8 ± 19.6 | 0.04 |
| prevalence of DO | 29/48 (60.4%) | 18/22 (81.8%) | 0.06 |
BOOI, bladder outlet obstruction index; DO, detrusor overactivity; IPP, intravesical prostatic protrusion; IPSS, International Prostate Symptom Score; LP, large prostate; OABSS, overactive bladder symptom scores; PVR, post-void residual urine volume; Qmax, maximum urinary flow rate; QOL, quality of life; PSA, prostate-specific antigen; SD, standard deviation; UFM, uroflowmetry.